AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 221 min read$RGEN

Loeillot Olivier sold $977K of RGEN

Loeillot Olivier (Chief Executive Officer) sold 5,426 shares of REPLIGEN CORP (RGEN) at $180.00 ($0.98M total) on 2026-09-21 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Loeillot Olivier
Published Sep 22, 2026, 8:07 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 22, 2026, 8:42 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$RGEN
Bearish
medium confidence
Mentioned
$RGEN
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RGENBearishLow
01

Why it matters

The disclosed sale may prompt short‑term selling pressure but likely limited given the modest amount relative to total holdings.

02

Market read

Primary insider sale filing; modest size but involves top executive, offering a low‑to‑moderate trading signal.

03

What to watch

The CEO retains 48,369 shares, representing a substantial stake that may mitigate concerns.

Relevance 4/10Novelty 5/10Timing: post‑market today

Background

Form 4 filing discloses insider transactions; such filings are primary sources for insider activity.

Company-level read

Ticker impact

$RGENBearishMedium confidence
Context

CEO Loeillot Olivier sold 5,426 shares for $976,680 on 2026-09-21 via a 10b5‑1 plan.

Expected impact

Potential short‑term dip of 1‑2% as the market digests the sale.

Evidence & confidence

The sale size is modest ($977k) but involves the chief executive, which often influences sentiment.

Market effects

Sector

Minimal impact on the biotech sector; only a slight bearish bias for peers.

Regional

U.S. market only; no broader regional effect.

Global

Low; limited to investors tracking insider activity.

Counterpoint

What could challenge this read

The sale could be a routine liquidity move under a pre‑arranged plan, not a confidence signal.

Key entities

  • person
    Loeillot Olivier

    Chief Executive Officer of Repligen Corp.

  • company
    Repligen Corp.

    Biopharmaceutical company listed on NASDAQ under ticker RGEN.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

RGEN insider trading history →

Related articles

OCT 6
$RGENHighAI 8/10

REPLIGEN CORP (RGEN): Completion of Acquisition or Disposition of Assets

REPLIGEN CORP (RGEN) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 REPLIGEN COMPLETES ACQUISITION OF BIOLIFE SOLUTIONS WALTHAM, MA - October 6, 2026 – Repligen Corporation (NASDAQ: RGEN, “Repligen”, or the “Company”), a life sciences company foc

SEC EDGAR 8-K2 min
OCT 6
$BLFSHigh

BIOLIFE SOLUTIONS INC (BLFS): Completion of Acquisition or Disposition of Assets

BIOLIFE SOLUTIONS INC (BLFS) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Item 2.01 Completion of Acquisition or Disposition of Assets. The information set forth in the “Explanatory Note” of this Current Report on Form 8-K is incorporated by reference into this Item 2.01. At the effective time of the First Merger (the “First Merger Effective Time”), ea

SEC EDGAR 8-K2 min
OCT 6
$RGENHighAI 8/10

Repligen Completes Acquisition of BioLife Solutions

Repligen Corporation (NASDAQ: RGEN) completed its acquisition of BioLife Solutions (NASDAQ: BLFS) for $11.25 per share in cash and 0.1442 shares of Repligen stock. The deal expands Repligen's presence in the cell therapy market, adding high-margin consumables and recurring revenue. BioLife's products support 18 approved therapies and most U.S. cell-based therapy trials. Repligen will discuss the transaction's financial impact on its Q3 2026 earnings call.

globenewswire.com1 min
OCT 5
$FRSHHighAI 8/10

Freshworks to Replace BioLife Solutions in S&P SmallCap 600

S&P Dow Jones Indices announced Freshworks (FRSH) will replace BioLife Solutions (BLFS) in the S&P SmallCap 600 on October 8, 2026. Repligen (RGN) is acquiring BioLife for $1.5B, with BioLife shareholders receiving $11.25 per share in cash and 0.1442 shares of Repligen stock. Freshworks reported Q2 2026 revenue of $237.4M, up 16% YoY, and its first GAAP profitability in 2026.

securities.io3 min